Gene therapy: a possible future standard for HIV care.

Despite undeniable accomplishments in developing cell and gene therapeutic strategies to combat HIV infection, key social, economic, and policy-related challenges still need to be overcome for any future commercialization efforts of these novel therapies to be successful. Here, we address these challenges and structure a framework for eradicating HIV/AIDS using gene therapy.

[1]  B. Slingsby,et al.  The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. , 2013, The Lancet. Global health.

[2]  Keiichiro Suzuki,et al.  Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells , 2015, Nature Communications.

[3]  J. Hoxie,et al.  Novel cell and gene therapies for HIV. , 2012, Cold Spring Harbor perspectives in medicine.

[4]  T. Quinn,et al.  Response to the AIDS pandemic--a global health model. , 2013, The New England journal of medicine.

[5]  N. Ford,et al.  Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Cynthia I. Grossman,et al.  Global action to reduce HIV stigma and discrimination , 2013, Journal of the International AIDS Society.

[7]  Supplement,et al.  Global Action to reduce HIV stigma and discrimination , 2013, Journal of the International AIDS Society.

[8]  S. Reeder,et al.  What nurse practitioners should know about gene therapy. , 2013, The Nurse practitioner.

[9]  I. Kerridge,et al.  Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J. Arcidiacono,et al.  US Food and Drug Administration international collaborations for cellular therapy product regulation , 2012, Stem Cell Research & Therapy.

[11]  M. Weinstein,et al.  HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? , 2014, PloS one.

[12]  Petra Reinke,et al.  A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. , 2014, Trends in molecular medicine.

[13]  R. Walensky,et al.  Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults , 2012, AIDS.

[14]  Petra Reinke,et al.  The business case for cell and gene therapies , 2014, Nature Biotechnology.

[15]  Jens Plahte.  Tiered pricing of vaccines: a win-win-win situation, not a subsidy. , 2005, The Lancet. Infectious diseases.

[16]  C. Murray,et al.  Absorptive capacity and disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant implementation , 2006, The Lancet.

[17]  J. Hoofnagle,et al.  Therapy for hepatitis C--the costs of success. , 2014, The New England journal of medicine.